%0 Journal Article
%T Twenty-four-month real-world visual outcomes of intravitreal aflibercept as monotherapy for the treatment of neovascular age-related macular degeneration
%A Manish Gupta
%A Mariam El Abiary
%A Radhika Patel
%A Thomas Siempis
%J Archive of "Oman Journal of Ophthalmology".
%D 2019
%R 10.4103/ojo.OJO_24_2018
%X Aflibercept is widely used as a treatment for neovascular age-related macular degeneration (nAMD). Nevertheless, there is no consensus in the optimal injection frequency in the 2nd year of treatment along with little real-world data on visual outcomes. On that basis, the primary aim of this study was to assess the visual acuity (VA) and the total number of injections needed on average for these patients during the 24-month follow-up
%K Aflibercept
%K age-related macular degeneration
%K antivascular endothelial growth factor
%K real word
%K visual outcomes
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561052/